Skip to main content
OpenTrials
Completed

NCT Number: NCT06720454

Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma

The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 40030, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pancreatic ductal adenocarcinoma
  • With post-operative paraffin specimens

Exclusion criteria

  • Other types of pancreatic cancer other than pancreatic ductal adenocarcinoma
  • Without post-operative paraffin specimens or less than 20% of the paraffin sections contain cancerous tissue

Treatment and study plan

Primary outcomes

  1. Intensity of immunofluorescence staining

    Time frame: From January 2019 to January 2024

    In this study, 68 pancreatic ductal adenocarcinoma tissues were used to detect the gene expression by multiple immunofluorescence staining

Sponsors and collaborators

Lead sponsor

Tiejun Ying

Other

Registry information

Official study title

Multiplex Immunofluorescence Staining of Pathological Tissue Microarray

Important dates

Study start
2019
Primary completion
2020
Study completion
2024
First posted
Dec 6, 2024
Registry last updated
Dec 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.